ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.
Reference
[1]. FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1.
ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.
Reference
[1]. FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1.